Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06989359
PHASE2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Sponsor: ADARx Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Official title: A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2025-08-28

Completion Date

2028-07

Last Updated

2026-03-02

Healthy Volunteers

No

Interventions

DRUG

ADX-038 Dose Level 2

siRNA duplex oligonucleotide

DRUG

ADX-038 Dose Level 1

siRNA duplex oligonucleotide

Locations (12)

ADARx Clinical Site

Shreveport, Louisiana, United States

ADARx Clinical Site

Shelby, Michigan, United States

ADARx Clinical Site

Dakota Dunes, South Dakota, United States

ADARx Clinical Site

Dallas, Texas, United States

ADARx Clinical Site

Houston, Texas, United States

ADARx Clinical Site

Wollongong, New South Wales, Australia

ADARx Clinical Site

Pok Fu Lam, Hong Kong

ADARx Clinical Site

Shatin, Hong Kong

ADARx Clinical Site

Gyeonggi-do, New South Wales, South Korea

ADARx Clinical Site

Seoul, New South Wales, South Korea

ADARx Clinical Site

Cheonan, South Korea

ADARx Clinical Site

Seoul, South Korea